ALNYLAM PHARMACEUTICALS, INC. 10-K

ITEM 2. PROPERTIES Our operations are based primarily in Cambridge, Massachusetts; Zug, Switzerland; Maidenhead, United Kingdom; Amsterdam, Netherlands; and Tokyo, Japan. A description of certain of the facilities we lease or own as of January 31, 2024 is included in the table below. Location Primary Use Approximate Square Footage Lease Expiration Date Renewal Option 675 West Kendall Street Henri A. Termeer Square Cambridge, Massachusetts Corporate headquarters and primary research facility 295,000 January 2034 Two five-year terms 300 Third Street Cambridge, Massachusetts Office space and additional research facility 129,000 January 2034 Two five-year terms 101 Main Street Cambridge, Massachusetts Office space* 61,000 March 2024 and June 2026 One five-year term on each lease 20 Commerce Way Norton, Massachusetts GMP manufacturing 200,000 Not applicable Not applicable 665 Concord Avenue Cambridge, Massachusetts GMP manufacturing** 15,000 September 2027 One five-year term Grafenauweg 4 6300 Zug, Switzerland International headquarters 14,500 March 2028 One five-year term Braywick Gate Braywick Road, Maidenhead Berkshire, United Kingdom Office space 21,500 May 2026 None Wisdom Cross Tower Antonio Vivaldistraat 150 Amsterdam, Netherlands Office space 12,500 April 2025 One five-year term Pacific Century Place 1-Chome-11-1 Marunouchi Chiyoda-ku Tokyo, Japan Office space 16,900 May 2025 None _________________________________________ * We lease office space located on the 12th and 13th floors at 101 Main Street, Cambridge, Massachusetts under a non-cancelable real property lease agreement by and between the Company and RREEF America REIT II CORP. PPP, dated as of April 15, 2015, or the Lease. On September 30, 2020, we entered into a First Amendment to the Lease, pursuant to which the term of the Lease with respect to the 12th and 13th floors was extended for an additional five years, through June 30, 2026. In addition, we have a separate lease agreement for the 10th floor at 101 Main Street, which expires in March 2024 and will not be extended. ** We manufacture ONPATTRO (patisiran) formulated bulk drug product at this location. In addition to the locations above, we also occupy small offices in multiple locations in and outside of the U.S. to support our operations and growth. In the future, we may lease, operate, purchase or construct additional facilities in which to conduct expanded research, development and manufacturing activities and support future commercial operations. We believe that the total space available to us under our current leases will meet our needs for the foreseeable future and that additional space would be available to us on commercially reasonable terms if required.